COBRE Center for Cancer Research Development

蛋白质组学核心 项目总结/摘要 罗得岛医院的COBRE CCRD蛋白质组学核心B（COBRE PC）提供了以下能力： 研究人员使用最新的质谱仪器进行蛋白质组学研究，从而 保持了罗得岛州的独特性。在第二阶段，仪器升级导致 放置Q Exactive Orbitrap LC-MS/MS系统以及UltraFlextreme MALDI TOF/TOF成像 质谱仪（Bruker Daltonics）使我们的研究人员能够从最先进的技术中受益 仪器仪表在第三阶段，核心将努力继续保持其出色的服务记录。详细 为核心小组制定了业务计划，并得到了该机构的财政支持， 保证让核心在第三阶段期间和之后蓬勃发展。建议的具体目标如下： 1.为了使仪器可用于最先进的蛋白质纯化和分析的研究人员在 罗得岛和东北地区的学术、临床和生物技术部门。 2.提供个人咨询，描述服务，参与实验设计，解释预期 调查结果，解释数据，并有助于校外资助工作，特别关注初级研究人员 获得CCRD的试点赠款核心D的支持。 3.提供蛋白质组学沿着分析/生物信息学工具的多样化和独特的服务， 指定的生物信息学家 4.在罗得岛医院以及更大的学术界推进转化研究 通过与CCRD的分子病理学核心C保持密切的工作关系，并鼓励 使用了核心肿瘤库的癌组织

Proteomics Core Project Summary/Abstract The COBRE CCRD Proteomics Core B (COBRE PC) at the Rhode Island Hospital provides the ability for investigators to perform proteomics studies using the latest instrumentation in mass spectrometry and thereby maintains its uniqueness to the state of Rhode Island. During Phase II, instrument upgrades led to the placement of a Q Exactive Orbitrap LC-MS/MS system as well as a UltraFlextreme MALDI TOF/TOF Imaging Mass Spectrometer (Bruker Daltonics) allowing our investigators to benefit from state-of-the-art instrumentation. The Core, during Phase III, will strive to continue its outstanding record of service. Detailed business plans have been formulated for the Core and financial support from the institution has been guaranteed to allow the Core to thrive during and after Phase III. The following specific aims are proposed: 1. To make instrumentation available for state of the art protein purification and analysis to researchers in the academic, clinical and biotechnology sectors in Rhode Island and the Northeast region. 2. To provide personal consultation to describe services, participate in experimental design, explain expected findings, interpret data and contribute to extramural funding efforts with a special focus on junior investigators who have obtained support from the CCRD's Pilot Grants Core D. 3. To provide diverse and unique service in proteomics along with analytic/bioinformatic tools with the addition of a designated bioinformatician. 4. To advance translational research at the Rhode Island Hospital as well as the greater academic community by maintaining a close working relationship with the CCRD's Molecular Pathology Core C and encourage the use of cancerous tissue from the Core's Tumor Bank.